search
Back to results

A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines

Primary Purpose

Influenza

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
H1N1 influenza A Vaccine (Split virion), Inactivated
Sponsored by
Sinovac Biotech Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Influenza

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy male or female aged 60 and older
  2. Be able to show legal identity card for the sake of recruitment
  3. Volunteers are able to understand and sign the informed consent

Exclusion Criteria:

  1. Cases, cured cases and close contact of influenza A (H1N1) virus
  2. Women of pregnancy, lactation or about to be pregnant in 60 days
  3. Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc
  4. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
  5. Autoimmune disease or immunodeficiency
  6. Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
  7. Diabetes mellitus (type I or II), with the exception of gestational diabetes
  8. History of thyroidectomy or thyroid disease that required medication within the past 12 months
  9. Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
  10. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  11. Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study
  12. Seizure disorder other than:

    • Febrile seizures under the age of two years old
    • Seizures secondary to alcohol withdrawal more than 3 years ago, or
    • A singular seizure not requiring treatment within the last 3 years
  13. Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen
  14. Guillain-Barre Syndrome
  15. Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
  16. History of any blood products or seasonal influenza vaccine administration within 3 months before the dosing
  17. Administration of any other investigational research agents within 30 days before the dosing
  18. Administration of any live attenuated vaccine within 30 days before the dosing
  19. Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing
  20. Be receiving anti-TB prophylaxis or therapy currently
  21. Axillary temperature > 37.0 centigrade at the time of dosing
  22. Psychiatric condition that precludes compliance with the protocol:

    • Past or present psychoses
    • Past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years
    • Disorder requiring lithium
    • Suicidal ideation occurring within five years prior to enrollment
  23. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Sites / Locations

  • Beijing Centers for Diseases Control and Prevention

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

H1N1 influenza A Vaccine (Split virion), Inactivated

Arm Description

15 μg H1N1 influenza A Vaccine (Split virion), Inactivated

Outcomes

Primary Outcome Measures

Evaluate immunogenicity of split-virion influenza A (H1N1)vaccine in elders

Secondary Outcome Measures

Evaluate Safety of split-virion influenza A (H1N1)vaccine in elders

Full Information

First Posted
October 29, 2009
Last Updated
March 13, 2013
Sponsor
Sinovac Biotech Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT01004653
Brief Title
A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines
Official Title
An Open-Label Clinical Trial With Split-virion Influenza A/H1N1 Vaccines in Healthy Elders
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Completed
Study Start Date
September 2009 (undefined)
Primary Completion Date
October 2009 (Actual)
Study Completion Date
November 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sinovac Biotech Co., Ltd

4. Oversight

5. Study Description

Brief Summary
A single center, Open-Label phase IV clinical trial is to be conducted in healthy elders (equal to or more than 61 years to evaluate the immunogenicity and safety of Sinovac's 15μg H1N1 influenza A Vaccine (Split virion), Inactivated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
H1N1 influenza A Vaccine (Split virion), Inactivated
Arm Type
Experimental
Arm Description
15 μg H1N1 influenza A Vaccine (Split virion), Inactivated
Intervention Type
Biological
Intervention Name(s)
H1N1 influenza A Vaccine (Split virion), Inactivated
Intervention Description
100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated
Primary Outcome Measure Information:
Title
Evaluate immunogenicity of split-virion influenza A (H1N1)vaccine in elders
Time Frame
Sep. 2009- Oct. 2009
Secondary Outcome Measure Information:
Title
Evaluate Safety of split-virion influenza A (H1N1)vaccine in elders
Time Frame
Sep. 2009- Oct. 2009

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male or female aged 60 and older Be able to show legal identity card for the sake of recruitment Volunteers are able to understand and sign the informed consent Exclusion Criteria: Cases, cured cases and close contact of influenza A (H1N1) virus Women of pregnancy, lactation or about to be pregnant in 60 days Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain Autoimmune disease or immunodeficiency Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids Diabetes mellitus (type I or II), with the exception of gestational diabetes History of thyroidectomy or thyroid disease that required medication within the past 12 months Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study Seizure disorder other than: Febrile seizures under the age of two years old Seizures secondary to alcohol withdrawal more than 3 years ago, or A singular seizure not requiring treatment within the last 3 years Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen Guillain-Barre Syndrome Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis) History of any blood products or seasonal influenza vaccine administration within 3 months before the dosing Administration of any other investigational research agents within 30 days before the dosing Administration of any live attenuated vaccine within 30 days before the dosing Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing Be receiving anti-TB prophylaxis or therapy currently Axillary temperature > 37.0 centigrade at the time of dosing Psychiatric condition that precludes compliance with the protocol: Past or present psychoses Past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years Disorder requiring lithium Suicidal ideation occurring within five years prior to enrollment Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Facility Information:
Facility Name
Beijing Centers for Diseases Control and Prevention
City
Beijing
ZIP/Postal Code
100013
Country
China

12. IPD Sharing Statement

Learn more about this trial

A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines

We'll reach out to this number within 24 hrs